Viewing Study NCT07219459


Ignite Creation Date: 2025-12-24 @ 2:46 PM
Ignite Modification Date: 2025-12-26 @ 8:39 AM
Study NCT ID: NCT07219459
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-10-21
First Post: 2025-10-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Visugromab, Nivolumab and a Tyrosine Kinase Inhibitor (TKI) Compared to Double Placebo and a TKI in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Sponsor: CatalYm GmbH
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module